Secondly, there has been a discussion about the tau radiotracer off-target binding characteristics, and the imaging findings of 18F-THK-5351 PET in stroke patients could be better elucidated if corresponding fluid biomarkers, tissue pathology, or other complement imaging results are available. This evidence concerns the gene MAPT and Stroke.